In certain diseases with multiple causative mutations, such as atypical HUS, determining the specific causative mutation can allow for stratification of the patient based on the known risk of recurrence (i.e., low for MCP mutations vs. high for CFH mutation). This evidence concerns the gene CFH and hemolytic-uremic syndrome.